Successful use of methylprednisolone for treating severe COVID-19

J Allergy Clin Immunol. 2020 Aug;146(2):325-327. doi: 10.1016/j.jaci.2020.05.021. Epub 2020 May 29.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / therapeutic use*
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • COVID-19
  • Child
  • Child, Preschool
  • China
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / physiopathology
  • Cytokine Release Syndrome / diagnosis
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / physiopathology
  • Cytokine Release Syndrome / prevention & control*
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant
  • Male
  • Methylprednisolone / therapeutic use*
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / physiopathology
  • SARS-CoV-2
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Methylprednisolone